Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary

Janos Papp1 · Marietta Eva Kovacs1,2 · Zoltan Matrai3 · Enikő Orosz4 · Miklós Kásler5 · Anne-Lise Børresen-Dale6,7 · Edith Olah1

Published online: 7 October 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Familial adenomatous polyposis (FAP) is a colorectal cancer predisposition syndrome with considerable genetic and phenotypic heterogeneity, defined by the development of multiple adenomas throughout the colorectum. FAP is caused either by monoallelic mutations in the adenomatous polyposis coli gene APC, or by biallelic germline mutations of MUTYH, this latter usually presenting with milder phenotype. The aim of the present study was to characterize the genotype and phenotype of Hungarian FAP patients. Mutation screening of 87 unrelated probands from FAP families (21 of them presented as the attenuated variant of the disease, showing \(<100\) polyps) was performed using DNA sequencing and multiplex ligation-dependent probe amplification. Twenty-four different pathogenic mutations in APC were identified in 65 patients (75 %), including nine cases (37.5 %) with large genomic alterations. Twelve of the point mutations were novel. In addition, APC-negative samples were also tested for MUTYH mutations and we were able to identify biallelic pathogenic mutations in 23 % of these cases (5/22). Correlations between the localization of APC mutations and the clinical manifestations of the disease were observed, cases with a mutation in the codon 1200–1400 region showing earlier age of disease onset (p \(<0.003\)). There were only a few, but definitive dissimilarities between APC- and MUTYH-associated FAP in our cohort: the age at onset of polyposis was significantly delayed for biallelic MUTYH mutation carriers as compared to patients with an APC mutation. Our data represent the first comprehensive study delineating the mutation spectra of both APC and MUTYH in Hungarian FAP families, and underscore the overlap between the clinical characteristics of APC- and MUTYH-associated phenotypes, necessitating a more appropriate clinical characterization of FAP families.

Keywords Familial adenomatous polyposis · Colorectal cancer · Germline mutations · APC · MUTYH · Genotype–phenotype correlations

Introduction

Familial adenomatous polyposis is a rare colorectal cancer (CRC) predisposition syndrome, giving rise to approximately 1 % of all CRC cases and showing a distinctive phenotypic heterogeneity. In its autosomal dominant form (FAP1, OMIM#175100) it is characterized by the presence of hundreds or thousands of adenomas in the large bowel, and also by associated extracolonic manifestations including desmoid tumors, dental and skin abnormalities, retinal
spots and malignant tumors of other organs. One of the colorectal polyps usually transforms into carcinoma at an early age [1–4]. A phenotypic variant of FAP1, called attenuated FAP (AFAP), shows less aggressive features, fewer (<100) adenomas, 10–15 years later at disease onset [5–7] and require distinct surveillance and clinical management approaches [8–10].

FAP1 is caused by germline mutations of the adenomatous polyposis coli (APC) gene, encoding a multifunctional gatekeeper tumor suppressor protein expressed in a wide variety of tissues. Constitutional pathogenic mutations are identifiable in 60–80 % of the classic FAP1 cases, but only in 10–30 % of AFAP patients [11–14].

In the past decade, a significant part of patients with (A)FAP without a detectable germline APC mutation have been found to carry biallelic mutations in the base excision repair gene MUTYH, a highly conserved DNA glycosylase involved in the repair of oxidative guanine damage. This discovery led to the description of FAP2 (OMIM#608456, usually known as MUTYH-associated polyposis, MAP), a recessively inherited phenotypic variant of familial adenomatous polyposis, with clinical features overlapping those of AFAP and classical FAP [14–19].

In the present study we examined the first set of (A)FAP patients from Hungary and one of the largest cohort from Central-Eastern Europe [20–25] in order to determine the mutational spectra of the APC and MUTYH genes diagnosed with colorectal polyposis to compare the clinical features of the mutation carriers and also to evaluate the respective roles of these genes in the inherited CRC burden in this Central-Eastern-European population.

**Methods**

**Patients and samples**

Individuals in this study were referred for genetic counselling and testing to the Department of Molecular Genetics at the National Institute of Oncology (Budapest, Hungary), through a 15-year service (1999–2014). All investigations have been carried out in agreement with internationally recognized guidelines, using study protocols approved by the Institutional Ethical Board. Written informed consent was provided by each patient. Included in this study were 87 patients from well-characterized familial adenomatous polyposis kindreds. The majority of cases presented the clinical symptoms of classical FAP, while 21 patients were diagnosed with <100 polyps and were classified as AFAP. Polyp counts are based on the endoscopic findings of gastroenterologists or on the reports of clinical pathologists. Since collecting family history information is still often neglected in the clinical practice, and self-reporting was also shown to be highly inaccurate [26, 27], reliable family history information gathered through past clinical records was available only for a minority of the patients/families involved. Therefore, this data was not used for the ab initio classification of the families.

**Mutation analysis**

DNA was extracted from blood samples of all consenting subjects using either the classic phenol–chloroform method or the ArchivePure DNA Blood Kit (5 Prime). The entire coding region and splice junctions of the APC gene were amplified by PCR (primer sequences are available upon request). Mutation screening was performed using direct bidirectional sequencing on an ABI 3130 Genetic Analyzer (Life Technologies). The presence of all mutations was confirmed using a different blood sample. Additionally, the coding region of APC was screened for genomic copy number aberrations using the MLPA (multiplex ligation-dependent probe amplification) Kit P043 (MRC-Holland), according to the manufacturer’s recommendations, and as described previously [28, 29].

All patients found negative for deleterious APC gene mutations were screened for the presence of variants in the MUTYH gene, again by PCR amplification and direct bidirectional sequencing of all coding exons and neighbouring splice sites. The biallelic nature of MUTYH variants (i.e. their trans status) was ascertained for cases carrying two different mutations by inspecting their presence/absence in first-degree relatives, whenever such samples were available. Copy number analysis of the gene was performed using the MLPA Kit P378 (MRC-Holland).

The novel or recurrent status of the point mutations was assessed by comparing our data with those available in variant databases: HGMD Professional 2013.3 (release date 27th Sept 2013, http://www.hgmd.cf.ac.uk); the InSiGHT Colon Cancer Gene Variant Databases [30] (http://chromium.liacs.nl/LOVD2/colon_cancer/home.php, Accessed on May-2014) and the APC mutation database [31] at http://www.umd.be/APC/ (accessed on May-2014).

**Characterization of large deletions**

To determine the exact lengths of deletions having both breakpoints within the APC gene, a combination of XL-PCR and sequencing by primer walking was applied, where all deletions required individual approaches in selecting the appropriate PCR cycle settings and primer designs. An example is outlined in the legend of Fig. 1.

Although the precise localization of the deletion breakpoints that extended over the 5′ and/or 3′ gene boundaries has not been determined, gene dosage assays were performed to estimate the lengths of these sequence
changes. Twenty-nine regions were used for copy number analyses from 7.6 MB upstream to 1.5 MB downstream of the APC gene, all selected from non-repetitive regions. Primer sequences and exact localization data are available upon request from the authors.

The first TaqMan-based gene dosage assays in our studies were performed as previously described [32]. At a later stage of our experiments, a different approach was preferred, and copy number determination was done using the robust dosage PCR (RD-PCR) methodology, in which the target locus and an internal control with known copy number are co-amplified [33, 34]. Briefly, PCR was performed in a duplex or triplex design containing primers for the target locus/loci and for an endogenous control with two copies. A touch-down setting was used in the amplification step: after initial denaturation and enzyme activation (95 °C for 15 min), 14 cycles were carried out with a denaturation step for 15 s at 95 °C, 20 s at the annealing temperature (starting from 62 °C and ending at 55 °C with 0.5 °C decrease per cycle), and extension for 30 s at 72 °C. This was followed by another 10 PCR cycles using 55 °C as annealing temperature (Multiplex PCR Kit, Qiagen). In order to decrease inter-individual variation, the DNA samples were heated (90 °C for 10 min) in 2 × TE (pH = 8.0) before adding the PCR mixture [35, 36]. The reaction products were run an Agilent 2100 Bioanalyzer (High Sensitivity DNA Kit, Agilent), and copy number status of the target amplicon was assessed by comparing ratio-of-yield measures for input templates, using three-four negative control samples in each experiment (representative examples are shown on Fig. 2). For regions tested using both of the above methods, results were in concordance with each other.

**Mutation nomenclature**

Naming of the variants complies with the recommendations of the Human Genome Variation Society [37, 38]:
Fig. 2 Approximate localization of large genomic deletions by robust dosage PCR (RD-PCR). a Examples of copy number determination at several regions in duplex and triplex RD-PCR assays. The electropherograms of the patient (case HFC208, red) were superimposed on those of a control sample (blue), and shifted slightly to the right for better visibility. The heights of the control peaks (C) were adjusted to the same level. The deletion for a given amplicon (names given under each peak, reflecting the position of the given marker) is seen as a ~50 % reduction of peak intensity (red diamonds). b Diagram showing the approximate size of two deletions (case HFC106: upper; and HFC208: lower). The distance of the markers from the APC gene is given on the X axis (in kilobases, using negative numbers for upstream and positive numbers for downstream markers), while Y axis indicates the copy numbers normalized for the average of three control samples. A 40–60 % reduction for a given marker indicates the presence of the heterozygous deletion (red bars). Not all samples were tested for all positions. (Color figure online)
sequence changes are named in relation to the longest cDNA reference sequences (NM_000038.5 for APC and NM_001128425.1 for MUTYH), while predicted changes at the protein level are given according to the corresponding protein reference sequences (APC: NP_000029.2 and MUTYH: NP_001121897.1).

Statistics

Differences between groups were calculated by comparison of means using the Student’s t test, with p values less than 0.05 considered significant.

Results

Patient characteristics

A total of 87 unrelated probands (52 males and 35 females) with familial adenomatous polyposis were included in this study. The median age of diagnoses was 27 years (ranging from 6 to 53 years). The majority of the patients (66/87, 76%) showed symptoms of profuse, classical polyposis with several hundreds or thousands of polyps in the large bowel, the rest could be classified as attenuated FAP (AFAP) cases with less than 100 adenomatous polyps present. Clinical data on extracolonic manifestations were only rarely available, but five cases were reported to have a known phenotypic variant of FAP (four probands with Gardner syndrome and one with Turcot syndrome). Available clinical and mutation data are summarized in Tables 1, 2 and 3.

Mutations of the APC gene

Mutation analysis using direct sequencing and MLPA revealed the presence of a deleterious sequence variant in the APC gene in 75% of the probands (65/87), with 52% (11/21) among the AFAP patients and 82% (54/66) among classical FAP probands. The mutation spectrum consists of nine genomic deletions (14%), and 56 point mutations. Three of the large deletions could be localized with both breakpoints within the APC gene and involving Alu repeat elements (Fig. 1), while the other six extended over the gene boundaries, half of them affecting neighbouring genes, two of them containing the entire APC sequence (Figs. 2, 3). Of the 56 point mutations, 32 were small indels, 19 were nonsense substitutions and 5 were variants predicted to lead to altered splicing. The point mutations represent 42 different pathogenic changes, 12 (29%) of them novel, one seen in two reportedly unrelated families. The most frequently occurring mutations (c.3183_3187del5; p.Gln1062* and c.3927_3931del5; p.Glu1309Aspfs*4) were seen in five probands each. A summary of the mutations found in our patients is given in Tables 1 and 2.

Biallelic MUTYH mutations

Twenty-two patients without evidence of pathogenic APC variants were analyzed for mutations in the MUTYH gene. Direct sequencing revealed five cases (23%) with biallelic MUTYH mutations, three carriers with the classical FAP phenotype and two from the AFAP group. None of the mutations were novel (Table 3).

Genotype–phenotype correlations

Patients with constitutional APC mutations showed a median age of 26 years (range 6–45 years) at disease onset, which significantly differed (p = 0.018) from that of the mutation negative cases (median 37 years, ranging from 7 to 53 years), and those with biallelic MUTYH mutation (median 46 years ranging from 35 to 51 years p = 0.029). Biallelic MUTYH mutation carriers showed no difference compared to mutation negative cases (p = 0.084).

Extracolonic manifestions were rarely reported, but three of the four Gardner syndrome cases described here (diagnosed with multiple adenomas together with desmoid tumors) were found to carry an inactivating APC mutation after codon 1400. The majority of AFAP cases were found to carry a pathogenic APC mutation located in the 5′ part of the gene (Table 1; Fig. 3). Regarding the association of the mutation position with the patients’ age at onset we demonstrated a significantly reduced age for those carrying a mutation in the 100 amino acid vicinity of codon 1300 as compared to those with mutations in other parts of the APC gene (p < 0.003) (Fig. 3).

Discussion

There is only limited information of the spectrum of APC and MUTYH mutations in the Central-Eastern-European region [20–25]. In this study the coding region of the APC gene has been screened for mutations in a panel of 87 unrelated probands diagnosed with familial adenomatous polyposis. The methods applied for mutation analysis included direct sequencing and also screening for copy number alterations using MLPA, and this combined approach allowed us to identify a pathogenic alteration in 75% of the patients analysed, with 82% of the classical FAP cases.

The scattered mutation pattern, the marked predominance of small deletions (more than half of the point mutations falling into that category) and also the relative frequency of large genomic alteration (14%) is in
Table 1 Pathogenic APC variants: substitutions and small indels

| Family | Age | Polyp | Pheno-type | Coding exon | Mutation | References |
|--------|-----|-------|------------|-------------|----------|------------|
| HFC005 | 25  | ++    | AFAP       | 3           | c.416_419del4 | p.Lys139Argfs*30 [39] |
| HFC068 | 43  | ++    | AFAP       | 3           | c.416_419del4 | p.Lys139Argfs*30 [39] |
| HFC201 | 42  | +++   | cFAP,G     | 4           | c.423-2A>G   | Skipping of exon 4 [40] |
| HFC127 | 34  | ++    | AFAP       | 4           | c.423G>T     | Skipping of exon 4 [41] |
| HFC043 | 44  | +++   | cFAP       | 4           | c.513_516del4 | p.Pro173* Novel |
| HFC024 | 40  | +     | AFAP       | 6           | c.646C>T     | p.Arg216* [42] |
| HFC024 | 40  | +     | AFAP       | 6           | c.694C>T     | p.Arg564* [43] |
| HFC122 | 23  | ??    | AFAP       | 7           | c.793G>T     | p.Gly265* Novel |
| HFC044 | 24  | +++   | AFAP       | 13          | c.1690C>T    | p.Arg564* [44] |
| HFC137 | 24  | ??    | AFAP       | 13          | c.1690C>T    | p.Arg564* [45] |
| HFC129 | 27  | ??    | AFAP       | 14          | c.1690C>T    | p.Arg216* [46] |
| HFC062 | 44  | +++   | AFAP       | 14          | c.1690C>T    | p.Arg564* [47] |
| HFC043 | 44  | +++   | cFAP       | 14          | c.1748dupC   | p.Thr584Asnfs*18 Novel |
| HFC144 | 18  | +++   | cFAP       | 15          | c.1886delT   | p.Leu629* [48] |
| HFC082 | 26  | +++   | cFAP       | 15          | c.2138C>G    | p.Ser713* [49] |
| HFC095 | 34  | +++   | cFAP       | 15          | c.2413C>T    | p.Arg805* [50] |
| HFC070 | 25  | +++   | cFAP       | 15          | c.2626C>T    | p.Arg805* [51] |
| HFC129 | 27  | +++   | cFAP       | 15          | c.2626C>T    | p.Arg805* [52] |
| HFC170 | 29  | +++   | cFAP       | 15          | c.2805C>G    | p.Arg805* [53] |
| HFC224 | 15  | +++   | cFAP       | 15          | c.3186_3187del5 | p.Tyr1143Ilefs*22 [54] |
| HFC038 | 13  | +++   | cFAP       | 15          | c.3203_3206del4 | p.Ser1063* Novel |
| HFC061 | 17  | ++    | AFAP       | 15          | c.3257_3258delAC | p.His1068Profs*32 Novel |
| HFC065 | 39  | +++   | cFAP       | 15          | c.3257_3258delAC | p.His1068Profs*32 Novel |
| HFC099 | 18  | +++   | cFAP       | 15          | c.3427delT   | p.Tyr1143Ilefs*22 [55] |
| HFC067 | 10  | +++   | cFAP       | 15          | c.3471_3474del4 | p.Glu1157Aspfs*75 [56] |
| HFC033 | 28  | +++   | cFAP       | 15          | c.3473_3474delAGA | p.Arg1158Thrfs*55 [57] |
| HFC212 | 30  | +++   | cFAP       | 15          | c.3682C>T    | p.Glu1128* [58] |
| HFC080 | 15  | +++   | cFAP       | 15          | c.3880C>T    | p.Glu1128* [59] |
| HFC042 | 19  | +++   | cFAP       | 15          | c.3925_3928del14 | p.Glu1309Argfs*11 [60] |
| HFC030 | 32  | +++   | cFAP       | 15          | c.3927_3931del5 | p.Glu1309Aspfs*4 [61] |
| HFC038 | 13  | +++   | cFAP       | 15          | c.3927_3931del5 | p.Glu1309Aspfs*4 [62] |
| HFC040 | 17  | +++   | cFAP       | 15          | c.3927_3931del5 | p.Glu1309Aspfs*4 [63] |
| HFC152 | 17  | +++   | cFAP       | 15          | c.3927_3931del5 | p.Glu1309Aspfs*4 [64] |
| HFC155 | 24  | +++   | cFAP       | 15          | c.3927_3931del5 | p.Glu1309Aspfs*4 [65] |
agreement with most previous findings in European populations [64–67]. The frequency of the two most commonly identified mutations at codon hot spots 1062 and 1309 in our sample set was 12 % each, which falls into the same range as reported by several other groups [66, 68, 69].

From the total of 42 unique point mutations, 12 were novel (29 %), which is in concordance with the wide range of this type of alterations found in different populations (from 16 % in Koreans to >40 % in Northern Europe) [52, 70, 71] and also with the frequencies appearing in the Human Gene Mutation Database. This relatively high frequency of novel alterations underscores the need of screening different populations in order to reveal their possibly distinct mutational spectra.

Detection of large genomic alterations are recently included more often in the routine mutation screening protocols then before, but the detailed characterization of these changes requires more time and dedicated techniques, which usually are outside the capacity of most laboratories. Thus, large genomic deletions are rarely studied in detail [64, 67, 72], although at least some of them may extend into neighbouring regions which potentially have a modifier effect on the disease phenotype as exemplified by some recent studies including our group [29, 32, 73–75]. In our series of cases, nine large genomic deletions were identified, varying widely in size, ranging from single exon deletions to an extremely large deletion containing many genes.

| Table 1 continued |
| --- |
| Family | Age | Polyp | Pheno-type | Coding exon | Mutation | References |
| HFC233 | 20 | +++ | cFAP | 15 | c.3939delT | p.Arg1314Glyfs*7 | Novel |
| HFC089 | 6 | +++ | cFAP | 15 | c.4057G>T | p.Glu1353* | [57] |
| HFC187 | 24 | +++ | cFAP | 15 | c.4067C>A | p.Ser1356* | UMD.be^d |
| HFC041 | 15 | ++ | AFAP | 15 | c.4099G>T | p.Gln1367* | [58] |
| HFC088 | 11 | +++ | cFAP | 15 | c.4268_4271del4 | p.Leu1423Glnfs*49 | Novel |
| HD001 | 19 | +++ | cFAP,G | 15 | c.4348G>T | p.Arg1450* | [59] |
| HFC213 | 42 | +++ | cFAP | 15 | c.4348C>T | p.Arg1450* | [59] |
| HFC200 | 27 | +++ | cFAP,G | 15 | c.4426delG | p.Val1476Phefs*31 | Novel |
| HFC018 | 20 | +++ | cFAP,G | 15 | c.4549C>T | p.Gln1517* | [60] |

Novel mutations are shown in italics

| Table 2 Pathogenic APC variants: large deletions |
| --- |
| Family | Age | Polyp | Exon | Mutation name | Repetitive elements |
| HFC132 | 42 | ++ | 4 | c.423-1108_532-2193del14086 | AluJh/AluS8 |
| HFC220 | 18 | +++ | 13–14 | c.1627-185_1958del651 | AluJr4/AluSz |
| HFC126 | 24 | +++ | 14 | c.1744-2465_1958+976del13656insGTAA | Non-Alu/AluSx1 |
| HFC145 | 45 | +++ | 0–13 | c.1-4?_1743+7del | Not determined |
| HFC184 | 22 | ++ | 0–13 | c.1-4?_1743+7del | Not determined |
| HFC203 | 32 | ++ | 0–13 | c.1-4?_1743+7del | Not determined |
| HFC110 | 13 | +++ | 14–15 | c.1-4?_8532+7del | Not determined |
| HFC106 | 26 | +++ | 0–15 | c.1-4?_8532+7del | Not determined |
| HFC208 | 33 | +++ | 0–15 | c.1-4?_8532+7del | Not determined |

a Age of diagnosis

b Number of polyps found at diagnosis (++: <30; ++: 30–100; +++: >100; NA: not available)

c Repetitive elements located at the 5'/3' breakpoints according to the RepeatMasker software [http://www.repeatmasker.org/]
Three of the large genomic alterations had both breakpoints located within the gene (deletion of exon 4, exon 14, and exons 13–14). For these cases we were able to determine the exact breakpoints, revealing a role of repetitive elements: different Alu sequences were involved in all cases, and in two instances a 4–6 bp non-template insertion at the breakpoint junction was also observed, indicating the classical non-homologous end joining (NHEJ) as the most likely mechanism responsible for these deletions [76–80].

The remaining six deletions extended over the gene boundaries, half of them reaching other upstream and/or downstream genes. The exact breakpoints were not specified, but we applied two independent semiquantitative techniques to determine the copy numbers (gene dosage) in several regions outside the APC gene, thus mapping the approximate sizes of these mutations. One of them (sample HFC208) was found to be more than 4 MB long and also affected the coding regions of several genes up- and downstream of APC (Fig. 4). Although some of these genes were indicated in colorectal carcinogenesis [2, 81, 82], their heterozygous deletion did not seem to cause any modification in the polyposis and/or CRC phenotypes of the probands carrying them. However, given the small number of patients carrying such large genomic deletions in our study, a considerably larger dataset would be required to reliably assess the potential role of these neighbouring genes.

From the 22 FAP/AFAP patients found negative for germline APC mutations, biallelic MUTYH mutations accounted for five (23 %) cases, increasing the overall mutation detection rate to 80 %. Of the two mutations most frequently reported in the literature to date, p.Tyr179Cys and p.Gly396Asp, (responsible for ~80 % of pathogenic variants found in European populations [83]), only the former was found in one case, emphasizing the need to determine the possibly characteristic population-specific mutation patterns by a comprehensive screening of the whole coding sequence for the gene for all populations studied.

Understanding genotype–phenotype correlations is useful for the clinical management of (A)FAP families [8–10], but the relationships between the locations of the APC mutations and certain extracolonic manifestations are still not fully delineated, and as more patients are diagnosed with (A)FAP, a broader range of extracolonic manifestations has come to be recognized in this group. For our sample set the extracolonic manifestations were rarely reported, so the only statistically significant correlation we

### Table 3 Biallelic MUTYH mutations

| Family   | Age<sup>a</sup> | Polyp<sup>b</sup> | Exon | Mutation name | Consequence (predicted) | References |
|----------|----------------|----------------|------|---------------|-------------------------|------------|
| HFC238   | 50            | +++           | 5    | c.504+19_504+31del13 | p.Lys155_Glu168del | [61]       |
|          | 9             |                | 7    | c.534G>A       | p.Arg245His           | [62]       |
| HFC006   | 51            | ++            | 6    | c.453_458dup   | p.Thr152_Met153insIleTrp | [17]     |
|          | 9             |                | 7    | c.734G>A       | p.Arg245His           | [62]       |
| HFC185   | 35            | +++           | 6    | c.453_458dup   | p.Thr152_Met153insIleTrp | [17]     |
|          | 10            |                | 10   | c.933+3A>C     | p.Gly264Trpfs*7       | [63]       |
| HFC239   | 30            | ++            | 7    | c.536A>G       | p.Tyr179Cys           | [15]       |
|          | 9             |                | 9    | c.734G>A       | p.Arg245His           | [62]       |
| HFC049   | 46            | +++           | 9    | c.734G>A       | p.Arg245His           | [62]       |
|          | 9             |                | 9    | c.734G>A       | p.Arg245His           | [62]       |

<sup>a</sup> Age of onset

<sup>b</sup> Number of polyps found at diagnosis (++: 30–100; +++: >100)
could demonstrate was the association between the age of disease onset and the location of the APC mutation in the codon 1200–1400 region, which is in agreement with several previous reports [46, 60, 84–87].

The inherent variability of the (A)FAP phenotype and also the overlap between APC- and MUTYH-linked phenotypes (that is, MUTYH mutations can be associated with classical FAP features) necessitate a more comprehensive approach for FAP screening to increase mutation detection yield. A combined analysis of the two genes with techniques allowing for the detection of both point mutations and large genomic alterations is needed for the exhaustive mutation testing of both classical FAP and attenuated FAP cases [13, 88, 89].

Finally, our patient series includes 17 families with no germline APC or MUTYH mutation detected, although ten of them belong to the classical FAP group with profuse polyposis. In these cases the age of disease onset was significantly older than that of the APC mutation carriers (34.5 vs. 26.7 years, \( p = 0.018 \)), and almost 10 years younger than those with biallelic MUTYH mutations (44 years). Since APC/MUTYH-negative cases are noticeably enriched in AFAP patients, while the mutation positive group in classical FAP cases, we also compared age of onset data separately for the FAP and AFAP groups, and found no significant difference between mutation negative and positive cases (\( p = 0.18 \) for the AFAP and \( p = 0.3 \) for the FAP group). Mutation negative cases raise the possibility of yet uncovered genetic heterogeneity of FAP, the possible role of other predisposing genes [90, 91], but also the incompleteness of the routinely used mutation screening techniques: ignored, but potentially regulatory regions in introns or even outside the gene boundaries may also contribute to inactivation of a predisposing gene [73, 92–96].

Acknowledgments The authors wish to thank the participants and their families for their cooperation. We thank Baloghné Kovács Mária, Frankó Judit, Ferenczéne Rab Judit and Domokos Gabriella for expert technical assistance. This work was supported by the Hungarian Research Grants KTIA-OTKA CK-80745, OTKA K-112228 (given to E.O.) and the Norwegian EEA Financial Mechanism, Hu0115/NA/2008-3/OP-9 (given to K.M., A.-L. B.-D. and E.O.).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M et al (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589–600
2. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A...
et al (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366–1370.

3. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253:661–665.

4. Nishikawa I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665–669.

5. Sprio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B et al (1993) Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75:951–957.

6. Fearnhead NS, Bisgaard ML, Bülows (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2:43–55.

7. Venesio T, Castells A (2015) Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol 12:88–97.

8. Leoz ML, Carballal S, Moreira L, Ocaña T, Balaguer F (2015) The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet 8:95–107.

9. Leoz ML, Carballal S, Moreira L, Ocaña T, Balaguer F (2015) The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet 8:95–107.

10. Nieuwenhuis MH, Vasen HF (2007) Correlations between MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 136:471–476.

11. Vasen HF, Mösllein G, Alonso A, Aretz B, Bernstein I, Bertario L, Blanco I, Bülows S, Burn J, Capella G et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713.

12. Claes K, Dahan K, Tejpar S, Bonduelle M, Abramowicz M, Verellen C, Franchimont D, Van Cutsem E, Kartheuser A (2011) The genetics of familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP). Acta Gastroenterol Belg 74:421–426.

13. Lucci-Cordisco E, Risio M, Venesio T, Genuardi M (2013) The genetic basis of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). Acta Gastroenterol Belg 74:421–426.

14. Papp J, Kovacs ME, Olah E (2007) Mutational spectrum in Hungarian Peutz–Jeghers Syndrome patients. BMC Med Genet 8:30.

15. Papp J, Kovacs ME, Olah E (2007) Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing. World J Gastroenterol 13:2727–2732.

16. Papp J, Kovacs ME, Olah E (2010) High prevalence of germline STK11 mutations in northern Italy. Tech Coloproctol 17:79–87.

17. Papp J, Kovacs ME, Olah E (2007) Mutational spectrum in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing. World J Gastroenterol 13:2727–2732.

18. Papp J, Kovacs ME, Olah E (2010) High prevalence of germline STK11 mutations in northern Italy. Tech Coloproctol 17:79–87.

19. de Leon MP, Urso ED, Pucciarello S, Agostini M, Nitti D, Roncucci L, Benatti P, Pedroni M, Kaleci S, Balsamo A, Laudi C, Di Gregorio C, Vial A, Rossi G, Venesio T (2013) Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. Tech Coloproctol 17:79–87.

20. Kohoutová M, Stekrová J, Jirásek V, Kapras J (2002) APC germline mutations identified in Czech patients with familial adenomatous polyposis. Hum Mutat 19:460–461.

21. Vandrovová J, Stekrová J, Kebrdllová V, Kohoutová M (2004) Molecular analysis of the APC and MYH genes in Czech families affected by FAP or multiple adenomas: 13 novel mutations. Hum Mutat 23:397.

22. Stekrová J, Sulová M, Kebrdllová V, Zídková K, Kotlas J, Ilenicová D, Vesela K, Kohoutová M (2007) Novel APC mutations in Czech and Slovak FAP families: clinical and genetic aspects. BMC Med Genet 8:16.

23. Sulová M, Zídková K, Kleibl Z, Stekrová J, Kebrdlová V, Bortlik M, Lukáš M, Kohoutová M (2007) Mutation analysis of the MYH gene in unrelated Czech APC mutation-negative polyposis patients. Eur J Cancer 43:1617–1621.

24. Pflausi S, Slomski R (2008) APC gene mutations causing familial adenomatous polyposis in Polish patients. J Appl Genet 49:407–414.

25. Schwarzová L, Štekrlová J, Florianová M, Novotný A, Schneidová M, Lneníčka P, Kebrdllová V, Kotlas J, Veselá K, Kohoutová M (2013) Novel mutations of the APC gene and genetic consequences of splicing mutations in the Czech FAP families. Fam Cancer 12:35–42.

26. Mitchell RJ, Brewster D, Campbell H, Porteous ME, Wylie AH, Bird CC, Dunlop MG (2004) Accuracy of reporting of family history of colorectal cancer, Gut 53:291–295.

27. Foo W, Young JM, Solomon MJ, Wright CM (2009) Family history? The forgotten question in high-risk colorectal cancer patients. Colorectal Dis 11:450–455.

28. Schouten JP, McElgunn CJ, Waaïjer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57.

29. Papp J, Kovacs ME, Olah E (2007) Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing. World J Gastroenterol 13:2727–2732.

30. Plazzer JP, Sijmons RH, Woods MO, Peltomäki P, Thompson B, Den Dunnen JT, Macrace F (2013) The InSiGHT database: utilizing 100 years of insights into Lynch syndrome. Fam Cancer 12:175–180.

31. Grandval P, Blayau M, Buisine MP, Coulet F, Maugard C, Pinson S, Remenieras A, Tinat J, Uhrhammer N, Béroud C, Olschwang S (2014) The UMD-APC database, a model of nation-wide knowledge base: update with data from 3,581 variations. Hum Mutat 35:532–536.

32. Papp J, Kovacs ME, Solyom S, Kasler M, Børresen-Dale AL, Ohal E (2010) High prevalence of germline STK11 mutations in Hungarian Peutz–Jeghers Syndrome patients. BMC Med Genet 11:169.

33. Liu Q, Li X, Chen JS, Sommer SS (2003) Robust dosage-PCR for detection of heterozygous chromosomal deletions. Biotechniques 34:558–562, 565–566, 568 passim.

34. Nguyen VQ, Shi J, Liu Q, Sommer SS (2004) Robust dosage (RD)-PCR protocol for the detection of heterozygous deletions. Biotechniques 37:360, 362, 364.

35. de Lellis L, Mammarella S, Curia MC, Veschi S, Mokini Z, Bassi C, Sala P, Battista P, Mariani-Costantini R, Radice P, Cama A (2012) Analysis of gene copy number variations using
Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in...
Castells A, Carracedo A, Ruiz-Ponte C (2009) Molecular analysis of the APC and MUTYH genes in Galician and Catalanian FAP families: a different spectrum of mutations? BMC Med Genet 10:57

Lagarde A, Rouele A, Ferrari A, Noguchi T, Qiu J, Briaux A, Bourdon V, Rémy V, Gaildrot P, Adélaïde J, Birnbaum D, Lidereau R, Sobol H, Olschwang S (2010) Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP. J Med Genet 47:721–722

Giarola M, Stagi L, Presciuttini S, Mondini P, Radice MT, Sala P, Pierotti MA, Bertario L, Radice P (1999) Screening for mutations of the APC gene in 66 Italian familial adenomatous polyposis patients: evidence for phenotypic differences in cases with and without identified mutation. Hum Mutat 13:116–123

Walls YL, Morton DG, McKeown CM, Macdonald F (1999) Molecular analysis of the APC gene in 205 families: extended genotype–phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36:14–20

Kanter-Smoler G, Fritzell K, Rohlin A, Engwall Y, Hallberg B, Bergman A, Meuller J, Grönborg H, Karlsson P, Björk J, Nordling M (2008) Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families. BMC Med 6:10

Andresen PA, Heimdal K, Aaberg K, Eklo K, Ariansen S, Silye S. Familien mit Lynch syndrome due to deletion of the 300 nucleotides of TACSTD1 constitute a distinct class of FAP. Int J Oncol 35:1463–1470

Takahashi M, Kikuchi M, Ohnami S, Ushiama M, Yoshida T, Sugano K, Iwama T, Kosugi A, Fausa O, Aabakken L, Aretz S, Eide TJ, Gedde-Dahl T Jr (2009) APC mutation spectrum of Norwegian familial adenomatous polyposis families: high ratio of novel mutations. J Cancer Res Clin Oncol 135:1463–1470

Wallis YL, Morton DG, McKeown CM, Macdonald F (1999) Molecular analysis of the APC gene in 205 families: extended genotype–phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36:14–20

Bertario L, Russo A, Sala P, Varesco L, Zuffardi O, Ranzani GN (2015) APC rearrangements in familial adenomatous polyposis: heterogeneity of deletion lengths and breakpoint sequences underlies similar phenotypes. Fam Cancer 14:41–49

Miki Y, Nishisho I, Miyoshi Y, Horii A, Ando H, Nakajima T, Utsunomiya J, Nakamura Y (1991) Frequent loss of heterozygosity at the MCC locus on chromosome 5q21-22 in sporadic colorectal carcinomas. Jpn J Cancer Res 82:1003–1007

Fukuyama R, Niculaita R, Ng KP, Obusez E, Sanchez J, Kalady M, Aung PP, Casey G, Sizemore N (2008) Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene 27:6044–6055

Out AA, Topping CM, Nielsen M, Weiss MM, van Munderhout JJ, Fokkema IF, Buïsine MP, Claeys K, Colas C, Fodde R, Fostira F, Franken P, Gaubatzdes M, Heimann K, Hodgson SV, Hogervorst FB, Holinski-Feder E, Lagerstedt-Robinson K, Olschwang S, van den Ouweland AM, Redeker EJ, Scott RJ, Vanekerbsilck B, Grolmund RV, Wijnen JT, Wikman FP, Arzet S, Sampson JR, Devilee P, den Dunnen JT, Hes FJ (2010) Leiden open variation database of the MUTYH gene. Hum Mutat 31:1205–1215

Friedl W, Meuschel S, Caspari R, Lamberti C, Krieger S, Sengstaller M, Propping P (1996) Attenuated familial adenomatous polyposis due to a mutation in the 3′ part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet 97:579–584

Brensinger JD, Laken SJ, Luce MC, Powell SM, Vance GH, Ahnen DJ, Petersen GM, Hamilton SR, Giardiello FM (1998) Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 43:548–552

Castells A, Carracedo A, Ruiz-Ponte C (2009) Molecular analysis of the APC and MUTYH genes in Galician and Catalanian FAP families: a different spectrum of mutations? BMC Med Genet 10:57

Bertario L, Russo A, Sala P, Varesco L, Girola M, Mondini P, Pierotti M, Spinelli P, Radice P, Hereditary Colorectal Tumor Registry (2003) Multiple approach to the exploration of genotype–phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21:1698–1707

Filipe B, Balthazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I, Mão de Ferro S, Claro I, Chaves P, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphry S, CORGI Consortium, WGS500 Consortium, Lucassen A, in the 300 nucleotides of TACSTD1 constitute a distinct class of FAP. Int J Oncol 35:1463–1470

Pierotti MA, Bertario L, Radice P (1999) Screening for mutations of the APC gene in 66 Italian familial adenomatous polyposis patients: evidence for phenotypic differences in cases with and without identified mutation. Hum Mutat 13:116–123

Walls YL, Morton DG, McKeown CM, Macdonald F (1999) Molecular analysis of the APC gene in 205 families: extended genotype–phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36:14–20

Kanter-Smoler G, Fritzell K, Rohlin A, Engwall Y, Hallberg B, Bergman A, Meuller J, Grönborg H, Karlsson P, Björk J, Nordling M (2008) Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families. BMC Med 6:10

Andresen PA, Heimdal K, Aaberg K, Eklo K, Ariansen S, Silye S. Familien mit Lynch syndrome due to deletion of the 300 nucleotides of TACSTD1 constitute a distinct class of FAP. Int J Oncol 35:1463–1470

Takahashi M, Kikuchi M, Ohnami S, Ushiama M, Yoshida T, Sugano K, Iwama T, Kosugi A, Fausa O, Aabakken L, Aretz S, Eide TJ, Gedde-Dahl T Jr (2009) APC mutation spectrum of Norwegian familial adenomatous polyposis families: high ratio of novel mutations. J Cancer Res Clin Oncol 135:1463–1470

Wallis YL, Morton DG, McKeown CM, Macdonald F (1999) Molecular analysis of the APC gene in 205 families: extended genotype–phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36:14–20

Bertario L, Russo A, Sala P, Varesco L, Girola M, Mondini P, Pierotti M, Spinelli P, Radice P, Hereditary Colorectal Tumor Registry (2003) Multiple approach to the exploration of genotype–phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21:1698–1707

Filipe B, Balthazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I, Mão de Ferro S, Claro I, Chaves P, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphry S, CORGI Consortium, WGS500 Consortium, Lucassen A,
Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I (2013) Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45:136–144 Erratum in: Nat Genet 45:713
91. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, van Zelst-Stams WA, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA, Kamping EJ, Nagtegaal ID, Tops BB, Nagengast FM, Geurts van Kessel A, van Krieken JH, Kuiper RP, Hoogerbrugge N (2015) A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 47:668–671
92. Tuohy TM, Done MW, Lewandowski MS, Shires PM, Saraiya DS, Huang SC, Neklason DW, Burt RW (2010) Large intron 14 rearrangement in APC results in splice defect and attenuated FAP. Hum Genet 127:359–369
93. Spier I, Horpaopan S, Vogt S, Uhlhaas S, Morak M, Stienen D, Draaken M, Ludwig M, Holinski-Feder E, Nothen MM, Hoffmann P, Aretz S (2012) Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. Hum Mutat 33:1045–1050
94. Pavicic W, Nieminen TT, Gylling A, Pursiheimo JP, Laiho A, Gynesei A, Jarvinen HJ, Peltomaki P (2014) Promoter-specific alterations of APC are a rare cause for mutation-negative familial adenomatous polyposis. Genes Chromosomes Cancer 53:857–864
95. Shirts BH, Salipante SJ, Casadei S, Ryan S, Martin J, Jacobson A, Vlaskin T, Koehler K, Livingston RJ, King MC, Walsh T, Pritchard CC (2014) Deep sequencing with intronic capture enables identification of an APC exon 10 inversion in a patient with polyposis. Genet Med 16:783–786
96. Snow AK, Tuohy TM, Sargent NR, Smith LJ, Burt RW, Neklason DW (2014) APC promoter 1B deletion in seven American families with familial adenomatous polyposis. Clin Genet. doi:10.1111/cge.12503